ArticleBlood cancer journal2015
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma.
Open access · goldAbstract readLetter
In one paragraph
Article in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).Cancer immunology, immunotherapy : CII · 2023Trial
- Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.International journal of clinical oncology · 2026Article
- Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma.Journal of clinical medicine · 2025Review
- Article
- PD-1 inhibitor in the treatment of relapsed primary mediastinal large B-cell lymphoma follow up byRadiology case reports · 2024Article
- Observational
- Article
- High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.Scientific reports · 2022Article
- An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features.Cancers · 2021Review
- Primary mediastinal large B cell lymphoma.Thoracic cancer · 2021Review
- Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.Blood advances · 2021Article
- Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.Blood advances · 2021Article
- Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma.Blood advances · 2021Article
- Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?Annals of translational medicine · 2020Article
- Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.Blood cancer journal · 2020Article
- Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review.Cancer management and research · 2020Article
- Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.British journal of haematology · 2019Review
- The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma.Therapeutic advances in hematology · 2019Review
- Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 1 country.
T AokiDepartment of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
K ShimadaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
R SuzukiCancer Center, Shimane University Hospital, Izumo, Japan.
K IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
A TomitaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Y MaedaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
J TakizawaDepartment of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
K MitaniDepartment of Hematology and Oncology, Dokkyo Medical University School of Medicine, Tochigi, Japan.
T IgarashiDepartment of Hematology and Oncology, Gunma Cancer Center, Oota, Japan.
K SakaiDepartment of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
K MiyazakiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
K MiharaDepartment of Hematology, Hiroshima University Hospital, Hiroshima, Japan.
K OhmachiDepartment of Hematology, Tokai University, Isehara, Japan.
N NakamuraDepartment of Pathology, Tokai University, Isehara, Japan.
H TakasakiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
H KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
S NakamuraDepartment of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan.
T KinoshitaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
M OguraDepartment of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Nagoya University · JPTokai University · JPAichi Cancer Center · JPDokkyo Medical University · JPGunma Children's Medical Center · JPHiroshima University Hospital · JPKanagawa Cancer CenterMie University · JPNagoya University Hospital · JPNiigata University · JPOkayama University Hospital · JPShimane University Hospital · JPShinshu University · JPTokai Central Hospital · JPToranomon Hospital · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Stem Cell TransplantationTransplantation, AutologousAdolescentAdultFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMediastinal NeoplasmsMiddle AgedRecurrenceRetrospective StudiesSurvival AnalysisYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.